Sandra Horning, MD
The China National Drug Administration (CNDA) has approved alectinib (Alecensa) for the treatment of patients with ALK
-positive, advanced non–small cell lung cancer (NSCLC), according to Roche, the manufacturer of the second-generation ALK inhibitor.
China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer. Roche. Published August 20, 2018. Accessed August 21, 2018. https://bit.ly/2BDO2bE.
... to read the full story